The 2026 ASCO Gastrointestinal Cancers Symposium (ASCO GI 2026) is being held January 8–10, 2026, at Moscone West in San Francisco, California, with both in-person and online participation available for the global GI oncology community.
Building on its reputation as a premier forum for gastrointestinal cancer research and clinical progress, ASCO GI 2026 convenes medical oncologists, surgeons, radiation oncologists, gastroenterologists, pathologists, radiologists, researchers, trainees, and patient advocates to spotlight advances spanning translational science, precision therapies, and multidisciplinary care.
Across scientific sessions, educational programming, and featured abstract presentations, the meeting highlights emerging data and practical insights across the spectrum of GI malignancies supporting timely knowledge-sharing and broad accessibility through its hybrid format.
Cathy Eng, VICC Associate Director of Strategic Relations and Research Partnerships at Vanderbilt-Ingram Cancer, shared some key highlights from the ASCO GI 2026:
“LBA284: ILUSTRO4 from Kohei Shitara with Zolbetuximab + FOLFOX + Nivo in met gastroesophageal cancer with encouraging
- PFS of 18M vs. 6.7M in cohort of 4B
- ORR = 62.1%
- Next: Phase III Lucerna”
“Phase III Herizon GEA-01 of Zani + chemo+ tisle for 1st line HER-2 locally adv/met gastroesophageal cancer
- Early trend for OS: 26.4 vs. 19.2M (HR = 0.80)
- PFS 12.4 vs. 8.1M with good tolerance”
“ASCO GI26 Keynote lecture at 2:30pm today with my friend and now CEO of The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute Kimryn Rathmell.
‘Meeting Patients with cancer where they are: the role of dyad partnerships.”
“Listening to Keynote GI26 re: how to improve our outreach re: clinical trial access and improve outcomes and treatment options.”
“I love this and so envious that Kimryn Rathmell can execute this with her leadership role at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research to improve clinical trial access especially for rare cancers. I would love to see more cancer centers emulate this approach and provide this type of infrastructure.”
“The primay reason I’m up so early is this amazng group from Fight Colorectal Cancer with an objective to support colon cancer awareness, education, cancer research, cancer prevention.”
“Day 1 of ASCO GI26 always honored to have so many of these amazing individuals as friends/colleagues. ONE mission = OMIT.”
“Adjuv immunotherapy vs. placebo for HCC for cCR radiographically or after surgery:
Keynote937
- No difference in OS (HR 1.06)
- Did not proceed to final analysis as the RFS hypothesis was not met
- No role for adjuvant IO.”
More posts about ASCO GI 2026.